164 related articles for article (PubMed ID: 36054561)
61. HDAC6 detector: online application for evaluating compounds as potential histone deacetylase 6 inhibitors.
Tinkov OV; Grigorev VY; Grigoreva LD; Osipov VN; Kolotaev AV; Khachatryan DS
SAR QSAR Environ Res; 2023; 34(8):619-637. PubMed ID: 37565331
[TBL] [Abstract][Full Text] [Related]
62. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
[TBL] [Abstract][Full Text] [Related]
63. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
[TBL] [Abstract][Full Text] [Related]
64. Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.
Cellupica E; Gaiassi A; Rocchio I; Rovelli G; Pomarico R; Sandrone G; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Bebel A; Airoldi C; Palmioli A; Stevenazzi A; Steinkühler C; Vergani B
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892072
[TBL] [Abstract][Full Text] [Related]
65. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
66. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
[TBL] [Abstract][Full Text] [Related]
67. Synthesis and structure-activity relationship of thiol-based histone deacetylase 6 inhibitors.
Guo Z; Zhang Y; Bao Y; Huang Z; Gu X; Wang G; Li J
Chem Biol Drug Des; 2022 Jul; 100(1):90-107. PubMed ID: 35404520
[TBL] [Abstract][Full Text] [Related]
68. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
69. Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.
De Vreese R; Galle L; Depetter Y; Franceus J; Desmet T; Van Hecke K; Benoy V; Van Den Bosch L; D'hooghe M
Chemistry; 2017 Jan; 23(1):128-136. PubMed ID: 27717044
[TBL] [Abstract][Full Text] [Related]
70. Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors.
Ediriweera MK; To NB; Lim Y; Cho SK
Biochimie; 2021 Jul; 186():147-156. PubMed ID: 33965456
[TBL] [Abstract][Full Text] [Related]
71. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
72. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
[TBL] [Abstract][Full Text] [Related]
74. A highly HDAC6-selective inhibitor acts as a fluorescent probe.
Ho YH; Wang KJ; Hung PY; Cheng YS; Liu JR; Fung ST; Liang PH; Chern JW; Yu CW
Org Biomol Chem; 2018 Oct; 16(42):7820-7832. PubMed ID: 30168823
[TBL] [Abstract][Full Text] [Related]
75. Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations.
Sixto-López Y; Bello M; Rodríguez-Fonseca RA; Rosales-Hernández MC; Martínez-Archundia M; Gómez-Vidal JA; Correa-Basurto J
J Biomol Struct Dyn; 2017 Oct; 35(13):2794-2814. PubMed ID: 27589363
[TBL] [Abstract][Full Text] [Related]
76. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Shen S; Kozikowski AP
Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
[No Abstract] [Full Text] [Related]
77. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
78. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
79. Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes.
Choi MA; Park SY; Chae HY; Song Y; Sharma C; Seo YH
Sci Rep; 2019 Sep; 9(1):13187. PubMed ID: 31515509
[TBL] [Abstract][Full Text] [Related]
80. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
